BofA analyst Tim Anderson raised the firm’s price target on Apogee Therapeutics (APGE) to $87 from $78 and keeps a Buy rating on the shares, citing estimate changes following Q2 results and rolling forward its base valuation year to 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Promising Prospects for Apogee Therapeutics: Buy Rating Backed by Strong Trial Results and Financial Health
- Apogee Therapeutics Faces Supply Chain Risks Amid Geopolitical Tensions and Regulatory Challenges
- Apogee Therapeutics Reports Promising Trial Results and Strong Cash Position
- Apogee Therapeutics reports Q2 net loss ($66.1M) vs ($33.816M) last year
- Apogee Therapeutics expects cash to fund operations into Q1 of 2028